Jpmorgan Chase & CO Kal Vista Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 20,940 shares of KALV stock, worth $243,532. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,940

Previous 90,560 76.88%

Holding current value

$243,532

Previous $1.07 Million 77.09%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$10.35 - $12.49 $720,567 - $869,553	-69,620 Reduced 76.88%	20,940 $246,000
Q1 2024 May 10, 2024	BUY	$11.07 - $16.04 $705,911 - $1.02 Million	63,768 Added 238.01%	90,560 $1.07 Million
Q4 2023 Feb 12, 2024	SELL	$7.58 - $12.25 $1.85 Million - $2.99 Million	-244,149 Reduced 90.11%	26,792 $328,000
Q3 2023 Nov 14, 2023	SELL	$8.95 - $11.35 $173,039 - $219,440	-19,334 Reduced 6.66%	270,941 $2.61 Million
Q2 2023 Aug 11, 2023	SELL	$7.73 - $10.57 $340,382 - $465,439	-44,034 Reduced 13.17%	290,275 $2.61 Million
Q1 2023 May 18, 2023	BUY	$6.3 - $8.39 $118,131 - $157,320	18,751 Added 5.94%	334,309 $2.63 Million
Q1 2023 May 11, 2023	SELL	$6.3 - $8.39 $72,103 - $96,023	-11,445 Reduced 3.5%	315,558 $2.48 Million
Q4 2022 Feb 13, 2023	BUY	$4.2 - $14.24 $801,397 - $2.72 Million	190,809 Added 140.1%	327,003 $2.21 Million
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $75,421 - $128,867	-7,657 Reduced 5.32%	136,194 $1.98 Million
Q2 2022 Aug 11, 2022	BUY	$8.16 - $15.1 $1.06 Million - $1.97 Million	130,427 Added 971.6%	143,851 $1.42 Million
Q1 2022 May 11, 2022	BUY	$11.2 - $16.97 $29,982 - $45,428	2,677 Added 24.91%	13,424 $198,000
Q4 2021 Feb 10, 2022	BUY	$12.36 - $18.28 $20,468 - $30,271	1,656 Added 18.22%	10,747 $142,000
Q3 2021 Nov 12, 2021	BUY	$17.11 - $24.49 $155,547 - $222,638	9,091 New	9,091 $159,000

Others Institutions Holding KALV

# of Institutions

121

Shares Held

48M

Call Options Held

71.8K

Put Options Held

26.3K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $286M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Kal Vista Pharmaceuticals, Inc. Transaction History